• Users Online: 32
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
  Most popular articles (Since July 27, 2015)

 
 
  Archives   Most popular articles   Most cited articles
 
Hide all abstracts  Show selected abstracts  Export selected to
  Viewed PDF Cited
PREFACE
Welcome to International Journal of Heart Rhythm
Zhang Shu
January-June 2016, 1(1):1-1
DOI:10.4103/2352-4197.191476  
  1,195 2,463 -
ORIGINAL ARTICLES
Antibiotic prophylaxis for permanent pacemaker implantation: A survey in chinese electrophysiological centers
Keping Chen, Xiaohan Fan, Wei Hua, Shu Zhang
July-December 2017, 2(2):62-67
DOI:10.4103/IJHR.IJHR_14_16  
Background: The practice of antibiotic prophylaxis for permanent pacemaker implantation varied widely in the real world of clinical practice due to no guidelines. The present study aims to investigate the use of antibiotic prophylaxis peri- and postimplantation of pacemaker in China. Materials and Methods: A total of 141 adult heart centers performing device implantation were asked using an E-mail or paper questionnaire to collect data regarding the use of antibiotics before or at implantation and duration of postimplantation. Subsequent telephone calls and E-mails were used to ascertain dubious data if necessary. Results: The final analysis included 135 centers (95.7% of total contacted) covering 7 main geographic regions of China. One hundred and twenty-six of the 135 centers (93.3%) used prophylactic antibiotics peri- and postimplantation. Among these centers, 107 centers (84.9%) selected first- or second-generation cephalosporins. In 100 centers (79.4%) of those used systemic antibiotics, an initial dose was given 0.5–2 h before surgery. With respect to duration of antibiotics administration, 99 centers of those used prophylactic antibiotics (78.6%) continued antibiotic therapy for 24–72 h while only 10 centers (7.9%) just administrated a single dose of antimicrobial agent before commencement of a procedure. Forty-eight of the 135 centers (35.6%) used intrapocket antibiotics at implantation, and gentamicin was the most commonly used antimicrobial agent (in 39/48 centers). Conclusion: Although the administration of prophylactic antibiotics before permanent pacemaker implantation has been implemented widely and routinely, our results showed that some electrophysiological centers still used no systemic antibiotic prophylaxis before or at the implantation. A significant difference exists in the timing, duration, and type of antibiotics use. Clinical trial evidence are required to guide optimal antibiotic prophylaxis for device implantation.
  2,890 193 -
Fragmented QRS complex in healthy adults: Prevalence, characteristics, mechanisms, and clinical implications
Ying Tian, Ying Zhang, Qian Yan, Jun Mao, Jianzeng Dong, Changsheng Ma, Xingpeng Liu
January-June 2017, 2(1):34-39
DOI:10.4103/2352-4197.208459  
Background: Fragmented QRS (fQRS) complex on a 12-lead electrocardiogram (ECG) is reportedly associated with myocardial scar or fibrosis in patients with structural heart disease. In healthy persons, however, the prevalence, underlying mechanisms, and clinical implications of fQRS remain unknown. Methods: In this prospective study, the routine 12-lead resting ECGs of 1500 consecutive healthy adults (707 male, age [38 ± 12] years) were independently screened for fQRS by two ECG readers. fQRS was defined as ≥1 additional deflection or notching within the QRS complex, including the peak of the R-wave or the nadir of S-wave, in at least two continuous leads. Results: fQRS was identified in 76 participants (5.1%) in a mean of (2.3 ± 0.7) leads, most commonly inferior leads (86.8%, 66/76), followed by precordial leads (13.2%, 10/76). Longer QRS duration and left deviation of the frontal QRS axis of ≤30° were identified as independent predictors of fQRS. In addition, fQRS in the precordial leads covered the QRS transition lead (from R/S <1 to R/S >1) in all ten participants. Sixteen healthy volunteers who were found to have fQRS underwent late gadolinium enhancement–cardiac magnetic resonance scanning, which revealed no myocardial fibrosis, scar, or other abnormalities. Conclusions: fQRS is not rare in healthy adults. The underlying mechanisms of fQRS in healthy adults seem to be mainly related to left axis deviation (especially deviations ≤30°), rather than myocardial scar or fibrosis.
  2,367 242 2
EDITORIALS
Multifocal atrial tachycardia: Looking for new solutions to an old problem
Elpidio Santillo
July-December 2017, 2(2):58-61
DOI:10.4103/IJHR.IJHR_2_17  
Multifocal atrial tachycardia (MAT) is a cardiac rhythm disorder frequently diagnosed in elderly patients affected by several comorbidities. However, MAT can be observed also in younger ages as an incidental finding or in association with heart and lung diseases. MAT is characterized by heart rate >100 beats/min and at least three different P waves when compared to sinus P wave. Recent guidelines recommend the use of beta-blockers and verapamil for rate control and ongoing management of MAT. Unfortunately, electrical cardioversion and antiarrhythmic drugs have been demonstrated not always effective in MAT treatment. Intravenous magnesium seems a promising therapy in restoring sinus rhythm in patients who developed MAT. Moreover, in the last years, innovative strategies such as atrioventricular junction modification, ablate and pace approach, and electrophysiological isolation of firing sites have been successfully tested as curative treatment in selected cases of MAT resistant to drug therapy.
  2,010 586 -
ORIGINAL ARTICLES
A Vector-Based Algorithm to Differentiate Septal and Free Wall Sites of Origin of Ventricular Arrhythmias in the Right Ventricular Outflow Tract
Fengxiang Zhang, Yan Xu, Zhen Fang, Liyan Zhao, Bing Yang, Hongwu Chen, Weizhu Ju, Mohammad Bilaal Toorabally, Kejiang Cao, Minglong Chen
January-June 2016, 1(1):43-49
DOI:10.4103/2352-4197.191481  
Purposes: There are few vector-based electrocardiogram (ECG) algorithms to differentiate ventricular tachycardia (VT) and premature ventricular complexes (PVCs) originating from the septum (SP) or free wall (FW) in the right ventricular outflow tract (RVOT). Methods: One hundred and twenty-one patients (mean age 41 ± 13 years; 62% female) underwent mapping and ablation of symptomatic PVC or VT with left bundle branch block morphology. Inferior axis and precordial lead transition zone ≥V3 on the ECG were analyzed retrospectively. Ablation was highly successful on the 95 SP patients and among 26 cases in the FW group. The ECG morphology of VT/PVC was analyzed to derive a novel algorithm to localize VT origin within the RVOT. A VT/PVC QRS axis ≥90° or an R wave amplitude ratios ≥1 in leads II and III predicted a septal origin. If neither of these characteristics were present, the following criteria were each given a score of 1: VT/PVC QRS axis <85;°, leads II and III R wave amplitude ratio <0;.88, QRS duration in lead III ≥155 ms, and QRS duration ≥155 ms in lead aVL. A cumulative score of ≥2 predicted an FW origin whereas a total score of <2; predicted an SP origin. A prospective analysis in 99 patients was used to confirm the significance of the algorithm. Results: Retrospective analysis showed that the new algorithm predicted an SP origin with an overall sensitivity, specificity, and positive predictive values of 95.2%, 88%, and 96.3%, respectively. Prospective analysis showed that the new algorithm predicted RVOT-SP origin with a sensitivity, specificity, and positive predictive values of 97.5%, 88.9%, and 97.5%, respectively. Conclusion: The new vector-based ECG algorithm can differentiate septal from FW sites of origin in the RVOT with a high sensitivity, specificity, and positive predictive values.
  2,209 277 -
GUIDELINE
Left Atrial Appendage Intervention for the Prevention of Thromboembolic Events in Patients with Atrial Fibrillation: A Joint Consensus Document of the Chinese Society of Pacing and Electrophysiology, Chinese Society of Cardiology, Chinese Society of Arrhythmias
Congxin Huang, Yong Huo, Shu Zhang, Kejiang Cao, Keping Chen, Minglong Chen, Hua Deng, Yansheng Ding, Jianzeng Dong, Pihua Fang, Xianhong Fang, Lianjun Gao, Wei Hua, He Huang, Dejia Huang, Hong Jiang, Jian Jiang, Chenyang Jiang, Li Li, Yigang Li, Qiming Liu, Shaowen Liu, Xingpeng Liu, Xu Liu, Yu Liu, Changsheng Ma, Jian Ma, Ju Mei, Xu Meng, Feifan Ouyang, Lihua Shang, Xi Su, Min Tang, Fang Wang, Huishan Wang, Yutang Wang, Zulu Wang, Gang Wu, Liqun Wu, Shulin Wu, Yunlong Xia, Yawei Xu, Jiefu Yang, Xinchun Yang, Yanzong Yang, Yan Yao, Kuijun Zhang, Shulong Zhang, Zhe Zheng, Shenghua Zhou
January-June 2016, 1(1):5-23
DOI:10.4103/2352-4197.191475  
  2,182 289 -
EDITORIAL
Rethinking Tilt Testing
Richard Sutton
January-June 2016, 1(1):2-4
DOI:10.4103/2352-4197.191478  
Tilt was used physiologically, 1930s–1970s, becoming a clinical diagnostic test for syncope in 1980s. Tilt has been criticized recently for failing to discriminate between reflex and more sinister syncope. Studies on possible benefit of pacing for older reflex syncope patients (2012–2014) yielded unexpected results. Patients with electrocardiogram implantable loop recorder (ILR) documented asystole and negative tilt, despite history strongly suggestive of reflex syncope, did well with pacing having syncope recurrence similar to that in paced His-Purkinje disease, while those with identical ILR findings and positive tilt did little better than those without pacing. These findings prompted explanation. The hypothesis hinged on tilt revealing a hypotensive/vasodepressor tendency rather than defining vasovagal syncope. Support was drawn from literature demonstrating good test sensitivity and specificity but no clinical value in arrhythmic, unexplained, or structural cardiovascular disease syncope. Further, in carotid sinus syndrome, another reflex syncope, the same pattern of disappointing pacing results was seen when tilt was positive but lack of syncope when tilt was negative. Thus, rethinking tilt testing is required to portray it in reflex, arrhythmic, unexplained, and cardiovascular syncope as having value in demonstrating risk of recurrence rather than being diagnostic. Its value in diagnosis of orthostatic hypotension (immediate/delayed), psychogenic pseudosyncope, and postural orthostatic tachycardia remains important and unchanged. The hypothesis has additional implications for management of hypertensive patients with syncope where medication may exacerbate symptoms requiring reduction/discontinuation. Tilt testing has greater value now than that claimed at its 1986 introduction.
  1,277 1,098 -
PERSPECTIVE
Risk Stratification of Sudden Cardiac Death: A Multi-racial Perspective
Dean M Abtahi, John Alvin Gayee Kpaeyeh, Michael R Gold
January-June 2016, 1(1):24-32
DOI:10.4103/2352-4197.191479  
Sudden cardiac death (SCD) is the leading cause of cardiovascular mortality and a major international health problem, with an estimated 3.7 million deaths occurring annually, accounting for approximately 15%–20% of all deaths worldwide. The implantable cardiac defibrillator (ICD) is an effective treatment of SCD and has had a major impact on outcomes. However, this therapy has been largely used in patients with left ventricular dysfunction. A changing epidemiology of SCD with fewer patients having marked reductions in left ventricular ejection fraction (LVEF) has renewed the focus on identifying other high risk populations. This article summarizes the current understanding of the diverse clinical, genetic, racial, electrocardiographic and imaging techniques available to detect patients most at risk. Despite many identified risk factors, no single predictor has been shown to have sufficient predictive value to be used to guide preventative therapy and reduce mortality. More recent effort has been directed towards combining markers to define a risk profile for identifying high risk cohorts.
  1,862 285 -
REVIEW ARTICLES
Prevention of sudden cardiac death after revascularization for coronary heart disease
Dejia Huang, Yong Huo, Shu Zhang, Congxin Huang, Yaling Han
January-June 2018, 3(1):1-15
DOI:10.4103/IJHR.IJHR_19_16  
Sudden cardiac death (SCD) is the leading cause of death in adults worldwide. Coronary heart disease is the underlying reason for most of the patients with SCD, including acute coronary syndrome and chronic ischemic heart disease. Revascularization is an important treatment technology for coronary heart disease, which includes percutaneous coronary intervention and surgical coronary artery bypass grafting. However, according to the recommended guidelines, even with the use of secondary prevention strategies such as medication treatment and a complete revascularization, there are still a great number of patients who have reduced left ventricular ejection fraction, heart failure, and ventricular arrhythmia at different stages in the course of disease. SCD remains to be a serious challenge in the long-term management of ischemic heart disease patients who have had revascularization. Here, we focus on broader issues of concerns to provide more insights by comprehensive recommendations for the clinical treatment of coronary artery disease after revascularization for SCD prevention.
  1,884 224 -
ORIGINAL ARTICLES
Implantation and Clinical Performance of an Entirely Leadless Cardiac Pacemaker
Chu-Pak Lau, Keping Chen, Kathy Lai-Fun Lee, Yan Dai, Shu Zhang
January-June 2016, 1(1):50-54
DOI:10.4103/2352-4197.191474  
Background: Entirely leadless pacemakers (LPMs) address limitations of conventional pacemakers that include complications related to the pacing leads, their connections, and pacemaker pockets. The aim of this study was to describe early implantation experience and clinical efficacy of LPM. Methods: A total of eight patients received an LPM (Micra™ Transcatheter Pacing System, Medtronic plc, Minneapolis, MN, USA). LPM was transvenously deployed using a 23 F sheath, and actively fixed by 4 nitinol tines. Results: On average, the patients were 74.3 ± 8.1 years, and 50% were female. All had indications for a ventricular demand (VVI) pacemaker, and ejection fraction was 66.4% ±7.4%. Except for one patient, all were implanted from the right femoral vein. The LPM was deployed either at the right ventricular apex (63%) or at the septum (37%). At implantation, pacing threshold at 0.24 ms was 0.69 ± 0.35 V, and R wave was 8.1 ± 2.9 mV. Successful pacing sites were reached at a median of 1 attempt (range 1–3), and the mean procedure and fluoroscopic times were 74 ± 19 min and 11.0 ± 5.8 min, respectively. 50% were on uninterrupted anticoagulation, and there were no acute complications including groin hematoma. Both pacing threshold and R wave improved at 1 month compared to acute implant value (0.46 ± 0.11 V and 14.5 ± 5.6 mV, respectively, P< 0.05 compared with implant). Between 1 and 3 months follow-up, there was no change in pacing or sensing threshold. The average percentage of ventricular pacing was 65% ± 26%. The intracardiac accelerometer was activated in 3/8 patients, and the satisfactory rate response profile during activity of daily living was achieved. Battery longevity was estimated to be more than 8 years in all patients. Conclusion This study documents excellent implantation success of the Micra™ LPM with stable pacing and sensing and satisfactory rate response profile.
  1,723 216 1
EDITORIALS
Contemporary versus tradition: Implantable cardioverter defibrillator use in nonischemic dilated cardiomyopathy
Chu-Pak Lau, Shu Zhang
July-December 2017, 2(2):53-57
DOI:10.4103/IJHR.IJHR_1_18  
  1,236 585 -
REVIEW ARTICLE
Silent Atrial Fibrillation: Unknown Truths
Hakan Aksoy, Ali Oto
January-June 2016, 1(1):33-37
DOI:10.4103/2352-4197.191477  
In recent years, silent atrial fibrillation (AF) has acquired broad interest in the neurologic and cardiovascular communities. Silent AF has been associated with similar morbidity and mortality as symptomatic AF and with similar rates of silent embolic events. In current clinical practice, AF remains mostly underdiagnosed, and 25% of patients with AF-associated cardioembolic stroke have not been previously diagnosed with AF. Silent AF detection methods include pulse palpation, ambulatory external electrocardiographic recordings, insertable cardiac monitors, and previously implanted cardiac devices with atrial lead. The increased interest is being directed toward detection of silent AF. Whether this will imply better outcomes for patients remains to be demonstrated.
  1,546 226 -
ORIGINAL ARTICLES
Effect of transcatheter closure of secundum atrial septal defect on cardiac electric remodeling
Shaimaa Ahmed Mostafa, Abdrabu Abdelhakim, Tarek Helmy Aboelazm, Osama Sanad Arafa, Ahmed M Elemam
January-June 2017, 2(1):40-48
DOI:10.4103/2352-4197.208453  
Purpose: This study aimed to investigate the intermediate- and short-term effects of transcatheter secundum atrial septal defect (ASD) closure on cardiac electric remodeling in children and adults. Methods: Fifty patients with secundum ASD referred for possible transcatheter device closure were subjected to history taking, proper physical examination, electrocardiographic assessment, and transthoracic echocardiographic examination and were evaluated before the ASD closure, 1 day, 3 months, and 6 months after closure. Results: During the 6-month follow-up, electrocardiographic parameters of remodeling were improved. P dispersion decreased from 49.73 ± 9.01 ms to 30.53 ± 5.08 ms (P = 0.004), QT dispersion decreased from 67.60 ± 5.31 to 51.13 ± 5.73 ms (P = 0.003), QRS duration decreased from 134.40 ± 4.97 ms to 116.20 ± 3.47 ms (P = 0.002), and PR interval decreased from 188.87 ± 6.06 ms to 168.00 ± 6.16 ms (P = 0.002). Electric remodeling was associated with remodeling of the cardiac chambers. At the end of follow-up, the right ventricular (RV) end-diastolic dimension decreased from 25.67 ± 5.50 mm to 17.80 ± 2.70 mm (P = 0.001) the left ventricular end-diastolic dimension increased from 33.17 ± 6.44 mm to 37.53 ± 5.15 mm (P = 0.002), mean pulmonary artery pressure decreased from 16.97 ± 3.37 mmHg to 9.22 ± 1.37 mmHg (P = 0.000), and RV systolic pressure decreased from 30.77 ± 4.69 mmHg to 18.8 ± 2.11 mmHg. After 6 months, 93.3% of the patients had normal RV size. Conclusion: Transcatheter ASD device closure leads to a significant improvement in the right-sided chambers' dimension and function and can reverse electrical changes in atrial and ventricular myocardium in children and adults after correcting hemodynamic status in short- and intermediate-term follow-up.
  1,575 178 -
Feasibility of an Elective Cardioversion Service Led by Advanced Practice Providers without Direct Cardiologist Supervision
Chad M House, Dennis W.X Zhu, Manish K Saha, Tarek S Hamieh, David G Benditt, William B Nelson
January-June 2016, 1(1):38-42
DOI:10.4103/2352-4197.191480  
Background: Elective direct current cardioversion (DCCV) has traditionally been performed by physicians in the United States. A few recent reports from the United Kingdom suggested that a specialist nurse-led service for elective DCCV of persistent atrial fibrillation was feasible. This practice has not been reported in the United States previously. Several years ago, we introduced a program where specially trained advanced practice providers (APPs) (physician assistants and nurse practitioners) assisted by an anesthesiology team, performed elective DCCV in patients with atrial fibrillation and atrial flutter, without direct cardiologist supervision. Methods: Upon receiving approval from the Institutional Review Board, we conducted a retrospective analysis of 447 consecutive DCCVs electively performed by APPs, for atrial fibrillation or atrial flutter, at Regions Hospital between 12/2006 and 10/2010. Transient deep sedation was administered by an anesthesiology team. The cohort was evaluated for procedural success and safety. Results: The procedural success rate was 92% (412/447). The incidence of procedural related adverse events, requiring immediate intervention, was 0.2% (1/447). This patient required emergent temporary pacing catheter insertion followed by a permanent pacemaker implantation at a later date. There were no other procedure-related complications and no thromboembolic events. A comparison with fifty elective cardioversions performed by cardiologists during the same period found no statistical difference in procedural success rates or complications. Conclusion: Under deep sedation administered by anesthesiology service, elective DCCV of atrial fibrillation and atrial flutter performed by well-trained APPs, without direct cardiologist supervision, is feasible and does not compromise patient safety.
  1,443 254 2
REVIEW ARTICLES
Evolution of left atrial appendage exclusion
Victor A Abrich, Dan Sorajja
January-June 2017, 2(1):22-28
DOI:10.4103/2352-4197.208457  
Atrial fibrillation is independently associated with an increased risk of thromboembolic stroke. While anticoagulants decrease this risk, they also carry a substantial risk of bleeding. Most left atrial thrombi arise from the left atrial appendage (LAA), which has led to several investigations into surgical and percutaneous methods of LAA exclusion for stroke reduction. The PubMed database was queried, and over 400 articles were considered for inclusion in this review. Of the surgical methods of LAA exclusion, complete excision is the most effective. Other methods, including ligation and stapling, may be incomplete and associated with left atrial thrombus formation. Surgical LAA exclusion has been commonly performed during mitral valve surgery although it has not been shown to prevent stroke in many retrospective studies. In patients unable to take warfarin, several percutaneous LAA exclusion devices have been studied, including the PLAATO system, Amplatzer Cardiac Plug (ACP), Watchman device, and Lariat. Both the ACP and Watchman have shown a significant stroke reduction and improved procedural safety with greater experience. The Lariat ligates the LAA using a combined endocardial and epicardial approach but is currently associated with substantial procedural risks. With better patient selection for the different options of LAA exclusion, thromboembolic stroke protection can be maximized with fewer complication risks.
  1,388 179 1
Magnetic resonance imaging-conditional devices: Where have we reached today?
Kamal K Sethi, Surendra K Chutani
January-June 2018, 3(1):16-24
DOI:10.4103/IJHR.IJHR_12_16  
Scientific growth in the field of magnetic resonance imaging (MRI) and cardiac devices has been exponential in recent decades. Cardiac implantable electronic devices due to their ferromagnetic constituents in leads and device body have always been an issue if patients need MRI. MRI is relatively safe. Recent introduction of changes in leads and device body constituents renders them less ferromagnetic, making MRI less frightening to a certain extent. Simultaneously, there is increasing research interest in MRI. Not only anatomy and pathology but also physiology of cardiac and nervous structures can be imaged. It is estimated that 53%–64% of intracardiac defibrillator (ICD) patients will require an MRI determination over a 10-year time horizon, highlighting the importance of MRI-conditional devices for this patient population. In this article, we briefly describe evolution and current status of conditioning of cardiac devices to make them MRI-friendly and briefly discuss where we are in terms of our physician role with respect to MRI-conditional devices.
  1,302 212 -
Latest technologies and techniques to improve pulmonary vein isolation
Ho-Chuen Yuen, Ngai-Yin Chan
January-June 2017, 2(1):13-21
DOI:10.4103/2352-4197.208460  
Pulmonary vein isolation (PVI) is the established cornerstone in catheter ablation for atrial fibrillation (AF). The traditional point-to-point ablation by focal radiofrequency (RF) catheter to achieve PVI was technically challenging, and the outcome remained suboptimal despite advancement in three-dimensional electroanatomical mapping systems and steerable sheaths. Different catheter designs including contact force, balloon-based catheters with other energy sources (cryothermal and laser energies), and circular RF catheters have been developed to make the ablation procedure more user-friendly and PVI more durable. Adjunctive techniques including detection of dormant conduction by adenosine triphosphate injection and pace-capture-guided ablation have also been studied to improve the durability of PVI and thus reduce the AF recurrence rate.
  1,310 149 -
Cardiac resynchronization therapy for the treatment of mild heart failure: A review of the clinical data
Timothy P Phelan, Judith A Mackall
January-June 2017, 2(1):5-12
DOI:10.4103/2352-4197.208455  
Cardiac resynchronization therapy (CRT) was originally established as an effective treatment for patients with systolic heart failure (HF) with New York Heart Association Class III–IV symptoms, reduced left ventricular ejection fraction and prolonged QRS duration ≥120 ms. Subsequent studies expanded the role of CRT to the treatment of patients with mildly symptomatic HF as these patients experienced similar improvement in clinical symptoms and reverse remodeling of the left ventricle. These clinical trial results were incorporated into the 2013 guidelines on cardiac pacing and CRT from the European Society of Cardiology and the 2012 American College of Cardiology Foundation/American Heart Association/Heart Rhythm Society Focused Update on Device-based Therapy of Cardiac Rhythm Abnormalities. Additional data from careful post hoc and substudy analyses as well as long-term follow-up of the original study cohorts have been performed. These results attempt to identify subgroups more likely to benefit from CRT, to define the association between response and QRS morphology/duration and to demonstrate the sustained benefit of CRT in this population. More importantly, these results highlight that patients with mildly symptomatic HF who respond to CRT not only have improvement in clinical symptoms but also receive a therapy that may prevent or delay progression of HF. A review of the clinical trials in mildly symptomatic HF and the results of subsequent post hoc analysis are summarized herein.
  1,088 166 -
ORIGINAL ARTICLES
The efficacy and safety of cardiac contractility modulation in patients with nonischemic cardiomyopathy: Chinese experience
Wei Hua, Xiaohan Fan, Yangang Su, Yujie Zhou, Jiangang Zou, Ji Yan, Xiaofei Li, Ligang Ding, Hongxia Niu, Shu Zhang
January-June 2017, 2(1):29-33
DOI:10.4103/IJHR.IJHR_13_16  
Background: Cardiac contractility modulation (CCM) has been used in patients with heart failure and normal QRS duration to improve exercise tolerance and quality of life. The safety and efficacy of CCM have been previously tested in moderate to severe heart failure patients with various etiologies in the western population. However, limited data are available on the safety and efficacy of CCM in Chinese patients with dilated cardiomyopathy and heart failure. Methods: Eight patients with dilated cardiomyopathy were prospectively enrolled to receive CCM implants from 5 hospitals in China. All patients had the New York Heart Association (NYHA) functional class III and IV heart failure, with left ventricular ejection fraction (LVEF) ≤35%, and QRS ≤ 120 ms. All patients were followed up at the 3rd and 6th month. Evaluation included the NYHA functional class, 6-min hall walk test (6MHW), Minnesota Living with Heart Failure (MLWHF) Questionnaire, and CCM parameters. Results: CCM was successfully implanted in all eight patients (50 ± 11 years, 6 men), and no device-related complications were observed in all patients at 3- and 6-month follow-up besides one patient voluntarily received heart transplantation at the 2nd month after CCM implantation and died from intracerebral hemorrhage during the perioperative period. Compared with baseline, the NYHA functional class (ΔNYHA: −1.0–−3.0, P= 0.016), the MLWHF quality of life scores (ΔMLWHF: −21.1 ± 17.5, P= 0.019), and 6MHW (Δ6MHW: 207.4 ± 202.5 m, P= 0.035) were significantly improved at 3-month follow-up. No significant change was observed in LVEF (ΔLVEF: −0.5%, 95% CI: −2.0%–12%, P= 0.813). All of these evaluations at 6-month follow-up were similar to those observed at 3-month, and no further improvement were observed from 3- to 6-month follow-up in the NYHA functional class (ΔNYHA 0; 0–1.0, P= 0.999), 6MHW (Δ6MHW: 39.2 ± 70.4 m, P= 0.231), MLWHF quality of life score (ΔMLWHF: 2.7 ± 3.9, P= 0.158), and LVEF (ΔLVEF: 2.0%, 95% CI: −2.0%–7.0%, P= 0.313). Conclusions: CCM might be a new choice of device treatment for Chinese patients with nonischemic cardiomyopathy and heart failure if they have normal QRS duration.
  1,094 151 -
EDITORIAL
Top ten studies of cardiac arrhythmia in 2016
Shu Zhang
January-June 2017, 2(1):1-4
DOI:10.4103/IJHR.IJHR_3_17  
  967 167 -
CASE REPORT
Clinical implications of real time implantable cardioverter-defibrillator high voltage lead short circuit detection
Roy Chung, Patricia D Garrett, Brian Wisnoskey, Mandeep Bhargava, Bruce L Wilkoff
January-June 2017, 2(1):49-51
DOI:10.4103/2352-4197.208454  
Implantable cardioverter-defibrillator lead failures are uncommon and predicting impending failure is challenging. We described a clinical case of a successful defibrillation despite initial detection of low high voltage impedance using Dynamic Tx algorithm, by withholding therapy if there is a short circuit and changing its shocking vector to an alternate one.
  897 174 1
ORIGINAL ARTICLES
Safety of continuing warfarin therapy in patients undergoing cardiac resynchronization therapy device implantation
Chad M House, Robert Gao, Imdad Ahmed, William B Nelson, Dennis W.X. Zhu
July-December 2017, 2(2):68-72
DOI:10.4103/IJHR.IJHR_5_17  
Background: Continuing warfarin therapy is considered safe for patient undergoing pacemaker or implantable cardioverter defibrillator procedures, but less evidence exists for patients undergoing cardiac resynchronization therapy (CRT) device implantation. Subjects and Methods: We retrospectively evaluated 136 consecutive patients who received a CRT device. Three periprocedural anticoagulation strategies were utilized: Group 1, continuation of therapeutic warfarin; Group 2, cessation of warfarin with heparin bridging; and Group 3, cessation of anticoagulation temporarily. Groups were compared on the incidence of complications. Results: Of the 136 patients, 87 (64%) were in Group 1, 18 (13%) were in Group 2, and 31 (23%) were in Group 3. Group 1 patients had an international normalized ratio of 2.3 ± 0.5, which was significantly higher than the other two groups. Coronary sinus dissection occurred in four patients: Three in Group 1 and one in Group 2, but no patient experienced pericardial effusion or tamponade. Group 2 experienced a higher incidence of pocket hematoma (P = 0.0065) and a longer length of hospital stay (P = 0.0069) than Group 1. Transient ischemic attack occurred in one patient in Group 3. Conclusion: Continuing warfarin with therapeutic international normalized ratio seems to be safe in individuals undergoing CRT device implantation.
  966 103 1
CASE REPORT
Phrenic nerve injury during cryoballoon ablation for paroxysmal atrial fibrillation originating from the superior vena cava
Xianxian Zhou, Ding Zhou, Hui Yang, Zhihong Wu, Zhenjiang Liu, Qiming Liu, Jian Ma, Shenghua Zhou, Xuping Li
January-June 2018, 3(1):34-37
DOI:10.4103/IJHR.IJHR_7_17  
Cryoballoon (CB) has emerged as a reasonable alternative to radiofrequency for treatment of paroxysmal atrial fibrillation (AF) due to simple operation, short learning curve, less patient discomfort, shorter ablation time, etc., However, the second-generation CB had a higher probability than the first-generation CB in the phrenic nerve injury (PNI) mostly observed in freezing the right superior pulmonary vein. Few reports on the CB ablation for a refractory AF originating from superior vena cava.what's more,It is rare to publish Phrenic Nerve Injury(PNI) is occurred in CB ablation for AF from SVC,the case is about it.
  875 121 -
REVIEW ARTICLES
Transvenous lead extraction: Barriers to care
Laurence M Epstein
January-June 2018, 3(1):25-29
DOI:10.4103/IJHR.IJHR_7_16  
The need for transvenous lead extraction (TVL) is increasing. Unfortunately, many patients with indications for extraction go without appropriate care. There are multiple barriers to patients receiving TVL. These include a knowledge deficit, a lack of adequate training, a lack of appropriate tools, and a lack of resources. In this paper, we will review these barriers and offer some potential solutions. Hopefully, in the near future, all patients that require TVL will be appropriately referred and the resources and training will allow safe and effective treatment.
  854 137 -
ORIGINAL ARTICLES
The real-time assessment of pulmonary vein isolation and safety of cryoballoon 3 versus cryoballoon 2 for atrial fibrillation: A systemic review and meta-analysis
Daobo Li, Chee Yuan Ng, Khalid Bin Waleed, Haixu Yu, Xumin Guan, Xiaojie Wang, Lianjun Gao, Xiaomeng Yin, Tong Liu, Yunlong Xia
July-December 2017, 2(2):73-80
DOI:10.4103/IJHR.IJHR_6_17  
Objectives: Cryoballoon ablation (CBA) has become a routine treatment option for paroxysmal atrial fibrillation (PAF). The third-generation CB (CB3) also known as “Arctic Front Advance ST” (CB-ST) was designed with a shorter distal tip. There have been several publications describing the characteristics of the CB3 system. We, therefore, undertook this systemic review and meta-analysis to compare the efficacy and safety of CB3 versus the second-generation CB (CB2) also known as “Arctic Front Advance.” Methods and Results: We performed a search on PubMed, Embase, and Web of Science database for studies published by August 2016 using the keywords “CB3,” “short-tip cryoballoon,” “Arctic Front Advance ST,” “CB3,” “cryoablation,” and “CBA.” Six studies with a total of 1625 patients were identified. There were 351 patients underwent CBA with CB3, and 1274 underwent CBA with CB2. Overall analyses indicated that there was a significant improvement in the real-time pulmonary vein isolation (RT-PVI) recording rate with CB3 compared to CB2 (odds ratio of 3.08, P < 0.00001). The procedure time (PT) was shorter for CB3 (weighted mean difference [WMD], 95% confidence interval CI: −10.27, [ − 19.2, −1.35], P = 0.02), while fluoroscopic time (WMD, 95% CI: 0.71, [ − 1.27, 2.68], P = 0.48) was not statistically different between the two groups. Conclusions: In this meta-analysis involving 1625 patients, the CB3 system decreased PT, enhanced RT-PVI recording rate while maintaining a similar safety profile.
  877 108 -